<DOC>
	<DOCNO>NCT01183728</DOCNO>
	<brief_summary>In prospective study aim evaluate feasibility safety implantation 40 million MSV knees osteoarthritis grade II-IV ( Kellgren Lawrence ) . The work hypothesis propose MSV antiinflammatory effect help heal articular cartilage degeneration grade enough objectivized questionnaire image procedure . The study quantitative change structure composition cartilage determine MRI T2-mapping ( Cartigram ) perform 6 , 12 24 month . Pain disability assess visual analogue scale ( VAS ) , WOMAC , Lequesne Index evaluation quality life Short Form 36 questionnaire ( SF-36 ) complete 3 , 6,12 24 month .</brief_summary>
	<brief_title>Treatment Knee Osteoarthritis With Autologous Mesenchymal Stem Cells</brief_title>
	<detailed_description>Knee osteoarthritis common form arthritis . Treatments involve high cost term social economic , palliative contemplate heal regenerative therapy . It show recently , mesenchymal stem cell ( MSC ) expand `` vitro '' may regenerate several damage injured tissue . In addition demonstrate MSC able modulate immune response control inflammation action T lymphocytes . Preliminary study animal model , include one carried equine research group , confirm feasibility , safety efficacy evidence propose treatment protocol . Our research group also experience prepare clinical-grade MSC bone marrow clinical trial necessary facility permission comply GMPs imposed recent EU legislation . Finally , clinical team wide experience regenerative therapy several previous clinical trial bone cartilage . We present alternative proposal , aim anti-inflammation regeneration injection single dose mesenchymal stem cell expand autologous bone marrow GMP-complying IBGM-Valladolid procedure ( MSV ) . Treatment involve two non-invasive surgical procedure low morbidity : obtain bone marrow local anesthesia sedation , 4 week later , articular injection cell product ( 20 million MSVs ) . The injection cell even require anesthesia obtain bone marrow require outpatient admission two hour follow safety criterion . Patients evaluate clinically , include pain score ( VSA ) , pain disability index ( WOMAC Lequesne ) life quality ( SF-36 ) , radiologic MRI procedure contrast allow quantification morphological structural change cartilage region study ( MRI T2-mapping ) . The design study open-label prospective , multicenter study . It recruit 12 patient osteoarthritis II-IV Kellgren Lawrence grade , Patients evaluate clinically previous study image ( X-rays MRI ) . If eligible study shall provide information clinical trial `` Patient Information Sheet , quote Inclusion Visit . In `` Inclusion Visit '' patient decide participate test sign Informed Consent Document schedule MRI X-rays schedule . The result exploration consider standard compare give change control 6 12 month . On visit , routine preoperative examination perform ( EKG , chest X-ray AP , basic analytic coagulation test identification HIV , Lues hepatitis B C valuation Internal Medicine Service ) . During visit V0 shall verify inclusion criterion persist exclusion criterion appear , shall program V1 ( obtain bone marrow ) provide preliminary date MSV injection 4 week later ( V2 ) . After application , patient follow-up schedule 8 day ( V3 ) , 3 ( V4 ) , 6 ( V5 ) , 12 ( V6 ) eventually 24 month ( V7 ) detail . V0 : Eligibility . Clinical History . Analysis , Imaging test . Programming follow visit V1 ( day 0 ) : Bone marrow aspiration local anesthesia sedation V2 ( day 23 ) . MSV Implantation . V3 ( +8 day Implantation ) : Security evaluation . V4 ( +3 month Implantation ) : Security evaluation . VAS , WOMAC , Lequesne Index , SF-36 questionnaire . V5 ( +6 month Implantation ) : Security evaluation . VAS , WOMAC , Lequesne Index , SF-36 questionnaire , RX , RNM . V6 ( +12 month Implantation ) : Security evaluation . VAS , WOMAC , Lequesne Index , SF-36 questionnaire , RX , RNM . V7 ( +24 month Implantation ) : Security evaluation . VAS , WOMAC , Lequesne Index , SF-36 questionnaire , RX , RNM .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Knee osteoarthritis grade II , III IV Kellgren Lawrence assess two observer . Chronic knee pain mechanical characteristic . No local systemic septic process . Haematological biochemical analysis without significant alteration contraindicate treatment . Informed write consent patient . The patient able understand nature study Age 75 18 year legally dependent Any sign infection Positive serology HIV1 HIV2 , Hepatitis B ( HBsAg , AntiHCVAb ) , Hepatitis C ( AntiHCVAb ) syphilis . Congenital acquire malformation result significant deformity knee lead problem application evaluation result . Overweight express body mass index ( BMI ) great 30.5 ( obesity grade II ) . BMI estimate mass ( kg ) / corporal surface ( m2 ) . Women pregnant intend become pregnant breastfeed Neoplasia Immunosuppressive state Participation another clinical trial treatment different investigational product within 30 day prior inclusion study . Other pathologic condition circumstance difficult participation study accord medical criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Knee degenerative disease</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>gonarthrosis</keyword>
	<keyword>stem cell</keyword>
	<keyword>cellular therapy</keyword>
	<keyword>regenerative therapy</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>musculoskeletal Diseases</keyword>
</DOC>